New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
08:10 EDTSNSS
theflyonthewall.com: Sunesis' Voreloxin receives FDA orphan drug designation
The FDA has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia. Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML. :theflyonthewall.com



News For SNSS From The Last 14 Days
Check below for free stories on SNSS the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
07:33 EDTSNSS
theflyonthewall.com: Sunesis grants Carmot Therapeutics license to Its drug discovery technology

Subscribe for More Information :theflyonthewall.com